ACIP releases interim 2013-‘14 influenza season recommendations
- Copyright © 2013, The American Academy of Pediatrics
The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has issued interim guidelines for the 2013-’14 influenza season, again recommending that anyone 6 months and older receive the influenza vaccine.
Four newly licensed influenza vaccines should be available for the upcoming season, ACIP announced. The new vaccines are acceptable alternatives to previously licensed products. ACIP does not recommend use of one product over another in cases where multiple vaccines are appropriate based on indications and age.
The new vaccines are:
Live, attenuated influenza vaccine, quadrivalent (LAIV4; FluMist Quadrivalent by MedImmune)
Inactivated influenza vaccine, quadrivalent (IIV4; FluarixC Quadrivalent, by GlaxoSmithKline)
Cell culture-based trivalent inactivated influenza vaccine (ccIIV3; Flucelvax, by Novartis)
Recombinant trivalent hemagglutinin influenza vaccine (RIV3; FluBlok, by Protein Sciences)
A complete list of all influenza vaccines currently licensed and expected to be available for the 2013-’14 season is available through the CDC at www.cdc.gov/flu/professionals/acip/2013-interim-recommendations.htm#table1. The information is current as of April 15.
ACIP approved the new vaccines at its February meeting. An expanded 2013 ACIP influenza recommendation statement will be released in the coming weeks.
The names of some vaccines reflect ACIP’s revised vaccine abbreviations.
The abbreviation TIV (trivalent influenza vaccine, previously used for inactivated influenza vaccines) has been replaced with the abbreviation IIV (inactivated influenza vaccine). For 2013-’14, IIVs as a class will include 1) egg-based and cell culture-based trivalent inactivated influenza vaccine (IIV3), and 2) egg-based quadrivalent inactivated influenza vaccine (IIV4).
RIV refers to recombinant hemagglutinin influenza vaccine, which will be available as a trivalent formulation (RIV3) for 2013-’14.
LAIV refers to live, attenuated influenza vaccine, which will be available as a quadrivalent formulation (LAIV4) for 2013-’14.
LAIV, IIV, and RIV denote vaccine categories; a numeric suffix specifies the number of influenza virus antigens contained in the vaccine.
Where necessary to refer specifically to cell culture-based vaccine, the prefix “cc” is used (e.g., “ccIIV3”).
More information on abbreviations is available at http://www.cdc.gov/vaccines/acip/committee/guidance/vac-abbrev.html.
Providers should check Food and Drug Administration-approved prescribing information and ACIP influenza recommendations for the most current information concerning indications, contraindications and precautions.
ACIP is a federal advisory committee comprised of physicians from across the country that provides expert external advice and guidance on vaccines to the CDC Director.